Search results
A tailored vaccine shows promise in treating childhood eczema
MedicalNewsToday via AOL· 7 days ago“Our work outlines new discoveries about how children with eczema respond immunologically to...
Large Cap Trio for Value, Growth and Yield
MoneyShow via Yahoo Finance· 2 days agoWith a solid economy and a Fed still likely to cut interest rates this year, we believe the dividend yield of 2.6% and forward P/E ratio of 14 on our portfolio holdings are attractive, especially ...
Nektar Therapeutics Reports First Quarter 2024 Financial Results
The Grass Valley Union· 5 days agoCash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to ...
Attovia secures $105m to advance development of lead programmes
Pharmaceutical Technology via Yahoo Finance· 5 days agoThrough initial clinical data readouts, Attovia will channel the funding proceeds towards advancing...
3i Symposium Inspires Interdisciplinary Insights i | Newswise
Newswise· 6 days agoCOVID-19 made it clearer than ever that infectious diseases and immunity are problems that require...
Biking revealed to be associated with less knee pain later in life
Medical Xpress· 1 day agoA study published in Medicine & Science in Sports & Exercise reveals that people who participated in...
Remarkable cancer breakthrough shows woman's brain tumor almost disappear in just five days
UNILAD· 1 day agoA team of researchers have revealed the 'dramatic responses' three cancer patients had to a new type...
Noxopharm scales up production of lupus drug SOF-SKN™ to GLP standards
Proactive Investors· 1 day agoNoxopharm Ltd (ASX:NOX, OTC:NOXOF) has reached a major drug development milestone in scaling up...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 2 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to...
The Longview News-Journal· 2 days ago- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders